Tociliuzumab

DRUG3 trials

Sponsors

Hoffmann-La Roche, Marmara University, Hu Yinan

Conditions

Antisynthetase SyndromeCOVID-19 PneumoniaTakayasu ArteritisTocilizumab

Phase 2

A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia

CompletedNCT04363736

Hoffmann-La RocheCOVID-19 Pneumonia

Start: 2020-05-05End: 2020-08-12Updated: 2022-08-31

Unknown Phase

Biologic Treatment Withdrawal in Takayasu Arteritis Patients in Sustained Remission

RecruitingNCT07491913

Marmara UniversityTakayasu Arteritis

Start: 2025-06-15End: 2027-12-15Target: 40Updated: 2026-03-25

Tocilizumab in Refractory ASS-ILD

CompletedNCT07662265

Hu YinanAntisynthetase Syndrome, Tocilizumab

Start: 2022-01-01End: 2025-10-31Updated: 2026-06-23

Related Papers

Antibody profiling of COVID-19 patients reveals antibodies and autoantibodies that may be associated with faster recovery from COVID-19

The Journal of Immunology2024-05-01

Safety and Efficacy of Tocilizumab 4 or 8 mg/kg in Hospitalized Patients With Moderate to Severe Coronavirus Disease 2019 Pneumonia: A Randomized Clinical Trial

Open Forum Infectious Diseases2021-12-0418 citations